Jevtana, Taxotere, Zytiga and Xtandi discussion – video from ASCO 2016

As we get ready for next weeks' American Society of Clinical Oncology annual meeting, I thought advanced prostate cancer patients would find it helpful to see this thirty minute review from last years meeting. Click >>>

By |2020-02-04T11:56:52-05:00May 23rd, 2017|Advanced Disease, Advanced Prostate Cancer|0 Comments

Xtandi May Work Better With TET

Androgen deprivation therapy (ADT) is a first line treatment for men when prostate cancer has spread beyond the prostate. Men die from prostate cancer after their disease becomes castration resistant prostate cancer (CRPC). Anti-androgen treatments such as Enzalutamide (Xtandi) have lengthened the life of thousands of advanced prostate cancer men around the world. Ultimately, even [...]

Quality of Life Improvements Help Extend Life While On Xofigo

You may live longer if you feel good about life while taking radium-223 (Xofigo). Dr Neal Shore from the Carolina Urologic Research Center studied how health related quality of life (HRQoL) might be related to overall survival while being treated for advanced prostate cancer with Xofigo. Approximately 800 men with advanced prostate cancer were asked [...]

Testosterone Levels May Predict Hormone Treatment Effectiveness

Advanced prostate cancer patients who started androgen deprivation treatment (ADT) treatment with low testosterone levels had worse 1-year progression-free and overall survival after continuous ADT than men with higher testosterone levels. This means that men who are about to start hormone therapy should have their testosterone tested. Those with low testosterone levels should ask their [...]

Step Ahead for Vaccine Therapy

Dendritic cells are replenished from blood  Dendritic cells help direct the body’s immune response by presenting invading antigens to T cells so they know what to attack. But an ongoing debate exists about where dendritic cells originate and how they multiply, especially in the spleen and lymph system. Now, in a paper published in this [...]